Client situation: A major infectious disease portfolio — the key revenue pillar of the business — needed comprehensive competitive monitoring across marketed assets expanding into additional indications and an active pipeline that needed to stay ahead of competitors.

Eradigm’s approach:

• Monitored strategy across a curated set of key players and competitive assets in a highly competitive therapy area
• Tracked regulatory, clinical, policy, and access shifts driving treatment dynamics
• Synthesised congress data into clear impact across the franchise
• Provided 9 regularly refreshed deliverables, 4 major congress coverages per year, and 46+ ad-hoc support pieces in a single year

What the client achieved:

• Franchise-level view: connecting insights across 13 marketed and 7 pipeline assets, not in silos
• Innovation-aware monitoring: tracking where the therapy area is moving, not just today’s threats
• Strategy-aligned outputs: insights built with and for brand and TA leadership, integrating buy-in from medical, R&D, and commercial functions

Client voice: “Our remit is so large and complex with stakeholders in constant need of CI support; Eradigm not only delivered with quality and responsiveness, but helped us shape our deliverables and processes internally.” — Strategy and Insights Director, major infectious disease franchise